Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
about
Pediatric Hodgkin lymphoma: biomarkers, drugs, and clinical trials for translational science and medicine.Idiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case ReportThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology ConsortiumEarly [¹⁸F]fluorodeoxyglucose positron emission tomography-based response evaluation after treatment with gemcitabine and vinorelbine for refractory Hodgkin disease: a children's oncology group report.Emerging Pharmacotherapy for Relapsed or Refractory Hodgkin's Lymphoma: Focus on Brentuximab VedotinBrentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome - a case report and discussionGemcitabine-induced radiation recall myositis in a patient with relapsed nasopharyngeal carcinomaManagement of relapsed and refractory classical Hodgkin lymphoma in children and adolescents.Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma.Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma.Essential medicines for pediatric oncology in developing countries.Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.A phase I/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma.
P2860
Q30248284-28E8DEB0-3960-4070-B014-807F41964AF8Q33424660-EA4542A3-C48B-4FC1-BB9D-AD4DC162AC29Q34240314-8513D6FF-C110-4573-B117-34E53EE9B487Q34477705-C46E1708-FD70-43B7-8E66-F05714FF0979Q34878992-5DA63C80-F287-4C66-BAA2-E4C5288774EDQ35669134-73318B95-97D3-41D7-AEF5-76946ACBA0FDQ35924909-691D2313-3B7D-4CF5-8F03-1C31CF7B61BEQ37507158-A473AE54-BBB0-411E-9732-6935B9152C1AQ37816470-E2701461-27A8-4B61-9C25-4C4AB742685EQ38068839-8F0AA23F-46B5-4ECC-A27F-088906797DC0Q38185983-250A469C-24CF-49EC-9A97-AF0FA26403F1Q42272922-38AEE670-D0C6-4D6F-9763-58C11C37F76AQ44120728-4786E040-E3B1-4E38-815D-E8D87C87F621Q45372995-894F32C8-F89C-4231-A9AF-8D27F42A27CC
P2860
Phase II study of weekly gemcitabine and vinorelbine for children with recurrent or refractory Hodgkin's disease: a children's oncology group report.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase II study of weekly gemci ...... ldren's oncology group report.
@en
Phase II study of weekly gemci ...... ldren's oncology group report.
@nl
type
label
Phase II study of weekly gemci ...... ldren's oncology group report.
@en
Phase II study of weekly gemci ...... ldren's oncology group report.
@nl
prefLabel
Phase II study of weekly gemci ...... ldren's oncology group report.
@en
Phase II study of weekly gemci ...... ldren's oncology group report.
@nl
P2093
P2860
P356
P1476
Phase II study of weekly gemci ...... ldren's oncology group report.
@en
P2093
Cindy L Schwartz
Pedro A de Alarcon
Peter D Cole
Richard A Drachtman
Tanya M Trippett
P2860
P304
P356
10.1200/JCO.2008.20.3778
P407
P577
2009-02-17T00:00:00Z